Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation

Cancer Gene Therapy

Volumn 17, Issue 7, 2010, Pages 501-511

  Whelan, M C ^a   Casey, G ^a   MacConmara, M ^b   Lederer, J A ^b   Soden, D ^a   Collins, J K ^a   Tangney, M ^a   O'Sullivan, G C ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

B7 1; Gene therapy; GM CSF; Immune therapy; Treg; Tumour

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; FIBROSARCOMA; GENE THERAPY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; GENETICS; HUMAN; IMMUNOGENETICS; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD80; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FIBROSARCOMA; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGENETIC PHENOMENA; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; GENETIC THERAPY;

EID: 77953693320     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.8     Document Type: Article

References (31)

1. Weiner LM. Cancer immunotherapy\the endgame begins. N Engl J Med 2008; 358: 2664-2665.
2. Murphy J, O'Sullivan GC, Lee G, Madden M, Shanahan F, Collins JK et al. The inflammatory response within Dukes' B colorectal cancers: implications for progression of micro-metastases and patient survival. Am J Gastroenterol 2000; 95: 3607-3614.
3. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007; 19: 203-208.
4. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006; 95: 896-905.
5. Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, Wunderlich JR et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006; 12: 5801-5808.
6. Collins CG, Tangney M, Larkin JO, Casey G, Whelan MC, Cashman J et al. Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors. Cancer Gene Ther 2006; 13: 1061-1071.
7. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201: 779-791.
8. Needham DJ, Lee JX, Beilharz MW. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 2006; 343: 684-691.
9. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L et al. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398-7405.
10. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121: 95-105.
11. Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 2006; 16: 106-114.
12. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19: 217-223.
13. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114: 1209-1217.
14. Bursuker I, North RJ. Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors. Cancer Immunol Immunother 1985; 19: 215-218.
15. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005; 54: 369-377.
16. Yang S, Vervaert CE, Seigler HF, Darrow TL. Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. Gene Ther 1999; 6: 253-262.
17. Cashman JP, Larkin JO, Casey G, Whelan MC, Collins C, Aarons S et al. Immune gene therapy as a neoadjuvant to surgical excision to control metastatic cancers. Cancer Lett 2008; 262: 94-102.
18. Winn HJ. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 1961; 86: 228-239.
19. Kohm AP, McMahon JS, Podojil JR, Begolka WS, DeGutes M, Kasprowicz DJ et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactiva-tion, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 2006; 176: 3301-3305.
20. Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, Woo SL. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 2007; 15: 2194-2202.
21. Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007; 67: 5929-5939.
22. Imai H, Saio M, Nonaka K, Suwa T, Umemura N, Ouyang GF et al. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007; 98: 416-423.
23. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-3633.
24. North RJ, Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2-suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 1984; 159: 1295-1311.
25. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200: 771-782.
26. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
27. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002; 107: 5-9.
28. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202: 885-891.
29. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
30. Liu A, Hu P, Khawli LA, Epstein AL. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res 2005; 11: 8492-8502.
31. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007; 67: 371-380.